<DOC>
	<DOCNO>NCT02648919</DOCNO>
	<brief_summary>The purpose study evaluate effect Noni extract men diagnose low risk low risk prostate cancer</brief_summary>
	<brief_title>Clinical Study Noni Extract Men With Very Low Risk Low Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Men diagnosis low risk ( &lt; 5 % risk disease relapse primary treatment , criterion ; cT1c , Gleason &lt; 6 , PSA &lt; 10 ng/mL , few 3 positive biopsy core &lt; 50 % cancer core , PSA density &lt; 0.15 ng/mL/g ) ; low risk ( 10 % risk disease relapse primary treatment , criterion ; cT12a , Gleason &lt; 6 , PSA &lt; 10 ng/mL ) prostate cancer 2 . Very low risk low risk group confirm Oncotype DX prostate cancer test provide Genomic Prostate Score ( GPS ) 3 . 60 year age old ( &gt; 60 year ) time inform consent 4 . No evidence extraprostatic disease 3T multiparametric pelvic MRI 5 . No baseline PT/PTT abnormality , coagulopathies , blood thinner . 6 . ECOG performance status 0âˆ’2 7 . Participants must normal organ marrow function demonstrate follow parameter : complete blood count ( CBC ) clinically significant finding complete metabolic profile ( CMP ) clinically significant finding lactate dehydrogenase ( LDH ) clinically significant finding 8 . Willing comply propose visit treatment schedule 9 . Able understand willing sign write informed consent document 1 . Prior history treat prostate cancer 2 . Concomitant use medication know CYP3A4 substrates 3 . Use medication supplement know affect PSA within 30 day prior informed consent , include toremifene citrate , finasteride , testosterone , dehydroepiandrosterone ( DHEA ) testosteronelike supplement . No dutasteride within 90 day prior inform consent 4 . Consumption concomitant nutritional , herbal supplement , antioxidant take discretion investigator . The following foods/supplements prohibit least 7 day prior initiation study treatment : St. John 's wort hyperforin ( potent CYP3A4 enzyme inducer ) Grapefruit juice ( potent cytochrome P450 CYP3A4 enzyme inhibitor ) 5 . Consumption use Noni Nonicontaining product 6 . History renal hepatic disease , include history hepatitis B C 7 . Participation investigational study use investigational agent within 30 day prior study entry 8 . History allergic reaction attribute Noni compound similar chemical biologic composition Noni , inactive component present Noni capsule . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychological , familial , sociological concomitant condition would allow adequate compliance study protocol</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>